EGFR and non-small cell lung carcinoma: Outstandingly, patients with EGFR+/EGF+, NeuGcGM3+/EGFR+, and NeuGcGM3+/EGFR+/EGF+ phenotypes of NSCLC displayed poor overall survival rates as compared with those with EGFR+/EGF−, NeuGcGM3+/EGFR−, and NeuGcGM3−/EGFR+/EGF+, respectively.